Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 13
2009 9
2010 20
2011 27
2012 31
2013 46
2014 53
2015 63
2016 65
2017 59
2018 59
2019 65
2020 89
2021 83
2022 97
2023 96
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

808 results

Results by year

Filters applied: . Clear all
Page 1
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. Tse C, et al. Cancer Res. 2008 May 1;68(9):3421-8. doi: 10.1158/0008-5472.CAN-07-5836. Cancer Res. 2008. PMID: 18451170
The oral bioavailability of ABT-263 in preclinical animal models is 20% to 50%, depending on formulation. ...In human tumor cells, ABT-263 induces Bax translocation, cytochrome c release, and subsequent apoptosis. ...
The oral bioavailability of ABT-263 in preclinical animal models is 20% to 50%, depending on formulation. ...In human tumor ce …
ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts.
Yang X, Xiao Y, Zhong C, Shu F, Xiao S, Zheng Y, Xia Z. Yang X, et al. Front Pharmacol. 2021 Jan 14;11:615505. doi: 10.3389/fphar.2020.615505. eCollection 2020. Front Pharmacol. 2021. PMID: 33519480 Free PMC article.
The objective of this study was to explore whether ABT-263 could target apoptosis of overactivated myofibroblasts in hypertrophic scar. ...Moreover, ABT-263 inhibited HSFs proliferation and reduced the expression of alpha-SMA and type I/III collagen in …
The objective of this study was to explore whether ABT-263 could target apoptosis of overactivated myofibroblasts in hypertrop …
ABT-263 exerts a protective effect on upper urinary tract damage by alleviating neurogenic bladder fibrosis.
Wen Y, Wu J, Pu Q, He X, Wang J, Feng J, Zhang Y, Si F, Wen JG, Yang J. Wen Y, et al. Ren Fail. 2023 Dec;45(1):2194440. doi: 10.1080/0886022X.2023.2194440. Ren Fail. 2023. PMID: 37154092 Free PMC article.
Sixty 12-week-old Sprague-Dawley (SD) rats were randomly divided into sham, sham + ABT-263 (50 mg/kg), NBF, NBF + ABT-263 (25 mg/kg, oral gavage), and NBF + ABT-263 (50 mg/kg, oral gavage) groups. ...Compared with the sham group, there wa …
Sixty 12-week-old Sprague-Dawley (SD) rats were randomly divided into sham, sham + ABT-263 (50 mg/kg), NBF, NBF + ABT- …
ABT-263 enhanced bacterial phagocytosis of macrophages in aged mouse through Beclin-1-dependent autophagy.
Zhang Y, Tang LH, Lu J, Xu LM, Cheng BL, Xiong JY. Zhang Y, et al. BMC Geriatr. 2021 Apr 1;21(1):225. doi: 10.1186/s12877-021-02173-2. BMC Geriatr. 2021. PMID: 33794800 Free PMC article.
METHODS: We treated the aged (12-16 months) and young (4-6 months) C57BL/6 mouse with ABT-263, then gave the animals cecal slurry injection to induce sepsis to observe the effect of senolytic compound ABT-263 on the survival rate of sepsis. ...Addition …
METHODS: We treated the aged (12-16 months) and young (4-6 months) C57BL/6 mouse with ABT-263, then gave the animals cecal slu …
ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells.
Lee YC, Wang LJ, Huang CH, Shi YJ, Chang LS. Lee YC, et al. Cancer Lett. 2018 Sep 28;432:191-204. doi: 10.1016/j.canlet.2018.06.019. Epub 2018 Jun 15. Cancer Lett. 2018. PMID: 29913235
The present study aimed to investigate the pathway related to MCL1 expression in ABT-263-treated human leukemia U937 cells. ABT-263 upregulated MCL1 protein expression but did not affect its mRNA level and protein stability. Notably, ABT-263
The present study aimed to investigate the pathway related to MCL1 expression in ABT-263-treated human leukemia U937 cells. …
ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C/EBP-homologous protein.
Yang IH, Jung JY, Kim SH, Yoo ES, Cho NP, Lee H, Lee JY, Hong SD, Shin JA, Cho SD. Yang IH, et al. Cell Oncol (Dordr). 2019 Jun;42(3):357-368. doi: 10.1007/s13402-019-00431-5. Epub 2019 Mar 27. Cell Oncol (Dordr). 2019. PMID: 30919222
PURPOSE: ABT-263 is a potent BH3 mimetic that possesses anticancer potential against various types of cancer. ...RESULTS: We found that ABT-263 suppressed viability and induced apoptosis in human oral cancer-derived cell lines HSC-3 and HSC-4. ...
PURPOSE: ABT-263 is a potent BH3 mimetic that possesses anticancer potential against various types of cancer. ...RESULTS: We f …
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. Souers AJ, et al. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6. Nat Med. 2013. PMID: 23291630
The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers. However, …
The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective in …
Navitoclax (ABT-263) Rejuvenates Human Skin by Eliminating Senescent Dermal Fibroblasts in a Mouse/Human Chimeric Model.
Takaya K, Ishii T, Asou T, Kishi K. Takaya K, et al. Rejuvenation Res. 2023 Feb;26(1):9-20. doi: 10.1089/rej.2022.0048. Epub 2023 Jan 16. Rejuvenation Res. 2023. PMID: 36324221
This study aimed to determine the rejuvenating effects of ABT-263 on aging skin using a human skin graft mouse model. We assessed the viability of ABT-263-treated skin fibroblasts after inducing senescence. ...ABT-263 is, thus, a novel po …
This study aimed to determine the rejuvenating effects of ABT-263 on aging skin using a human skin graft mouse model. We asses …
Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse Salmonella typhimurium Model.
Johnson LA, Rodansky ES, Tran A, Collins SG, Eaton KA, Malamet B, Steiner CA, Huang S, Spence JR, Higgins PDR. Johnson LA, et al. Inflamm Bowel Dis. 2022 Feb 1;28(2):161-175. doi: 10.1093/ibd/izab166. Inflamm Bowel Dis. 2022. PMID: 34302470 Free PMC article.
Finally, the therapeutic efficacy of ABT-263 was evaluated in the mouse Salmonella typhimurium intestinal fibrosis model. ...Intestinal fibrosis is a common complication of Crohn's disease, yet no effective therapies exist to treat fibrostenotic disease. We report …
Finally, the therapeutic efficacy of ABT-263 was evaluated in the mouse Salmonella typhimurium intestinal fibrosis model. ...I …
Next Generation Therapeutics for the Treatment of Myelofibrosis.
Tremblay D, Mascarenhas J. Tremblay D, et al. Cells. 2021 Apr 27;10(5):1034. doi: 10.3390/cells10051034. Cells. 2021. PMID: 33925695 Free PMC article. Review.
We focus on the mechanism, preclinical rationale, and available clinical efficacy and safety information of relevant agents including those that target apoptosis (navitoclax, KRT-232, LCL-161, imetelstat), epigenetic modulation (CPI-0610, bomedemstat), the bone marrow micr …
We focus on the mechanism, preclinical rationale, and available clinical efficacy and safety information of relevant agents including those …
808 results